VBI Vaccines, Inc.

( )
VBIV PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -5.93%158.000.0%$686.24m
AMGNAmgen, Inc. -0.25%250.581.5%$604.45m
GILDGilead Sciences, Inc. -0.47%66.021.0%$437.82m
VRTXVertex Pharmaceuticals, Inc. -1.24%299.231.9%$414.73m
REGNRegeneron Pharmaceuticals, Inc. -1.91%636.342.6%$364.61m
ILMNIllumina, Inc. -3.10%213.023.3%$317.77m
SNSSSunesis Pharmaceuticals, Inc. -0.98%4.060.7%$283.81m
NVAXNovavax, Inc. -8.19%39.3775.7%$258.88m
BIIBBiogen, Inc. -0.94%217.581.8%$192.12m
BNTXBioNTech SE -5.19%152.040.0%$149.19m
GOVXGeoVax Labs, Inc. 0.44%2.260.0%$119.92m
BMRNBioMarin Pharmaceutical, Inc. -0.20%94.844.2%$100.34m
SAVACassava Sciences, Inc. 27.26%25.720.0%$95.08m
CRSPCRISPR Therapeutics AG -5.42%71.740.6%$92.05m
PACBPacific Biosciences of California, Inc. -4.88%7.616.2%$87.70m

Company Profile

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.